QLT announces MGH litigation settlement
25 Noviembre 2009 - 6:00AM
PR Newswire (US)
VANCOUVER, Nov. 25 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ:
QLTI; TSX: QLT) ("QLT" or the "Company") today announced the
settlement of its litigation with the General Hospital Corporation,
doing business as Massachusetts General Hospital ("MGH"). Under the
terms of the settlement agreement, QLT will pay US$20.0 million to
MGH as payment in full for all past and future royalty obligations
under the License Agreement between QLT and MGH, in exchange for
the dismissal with prejudice of MGH's lawsuit against QLT pending
in the Massachusetts District Court for violation of Massachusetts
General Law Chapter 93A, sections 2 and 11. As part of the
settlement, QLT and MGH have also released each other from any
claims in connection with the lawsuit and certain related matters.
Under the existing License Agreement, QLT was obligated to pay MGH
a 0.5% royalty on Visudyne(R) sales in the U.S. and Canada. "We are
pleased to put this matter behind us and continue to concentrate on
our clinical programs and strategic growth initiatives," said Bob
Butchofsky, President and Chief Executive Officer of QLT. "We
believe that this agreement fairly resolves our dispute and serves
to recognize the critically important contributions made by MGH in
the development of Visudyne." About QLT QLT Inc. is a
pharmaceutical company dedicated to the development and
commercialization of innovative therapies for the eye. We are
focused on our commercial product Visudyne(R) for the treatment of
wet-AMD, and the development of drugs to be delivered in our
proprietary punctal plug devices. For more information, visit our
website at http://www.qltinc.com/. Visudyne is a registered
trademark of Novartis AG. QLT Inc. is listed on The NASDAQ Stock
Market under the trading symbol "QLTI" and on the Toronto Stock
Exchange under the trading symbol "QLT." DATASOURCE: QLT Inc.
CONTACT: QLT Inc., Vancouver, Canada, Karen Peterson, Telephone:
(604) 707-7000 or 1-800-663-5486, Fax: (604) 707-7001, ; The Trout
Group Investor Relations Contact: New York, USA, Christine Yang,
Telephone: (646) 378-2929, ; or Marcy Nanus, Telephone: (646)
378-2927,
Copyright